Updated:
Personalis
Personalis was founded in 2010 by Euan Ashley, Russ Altman, and Michael Snyder — three Stanford professors who saw that next-generation sequencing could...
Personalis
Personalis was founded in 2010 by Euan Ashley, Russ Altman, and Michael Snyder — three Stanford professors who saw that next-generation sequencing could decode cancer immunology at a resolution panel tests missed. The company’s platform sequences not just DNA but RNA and the tumor microenvironment, producing what it calls ImmunoID NeXT — a readout of 20,000 genes and the immune-cell repertoire in a single sample. This depth made it the sole sequencing partner for the Veterans Affairs Million Veteran Program, a landmark 1-million-genome longitudinal study that began delivering revenue in 2020 and now spans oncology, cardiovascular, and metabolic cohorts under a contract running through 2025. The core commercial strategy is biopharma services — providing companion diagnostic development and retrospective trial analysis. As of its 2023 annual report, Personalis counted Merck, Moderna, and a large undisclosed top-5 pharma among its enterprise customers, with active programs in colorectal cancer, melanoma, and solid tumors. The clinical diagnostic business, which offers a reimbursed, Medicare-covered genomic profiling test sold through a small U.S. sales team, accounted for roughly 25% of revenue in 2023. The company’s installed base includes over 50 biopharma accounts and 10 clinical trial sponsors using NeXT across Phase I through III studies. Hall joined in February 2023 after leading the Illumina-acquired GRAIL’s financing and growth operations; within five months he launched NeXT Dx V2, a Medicare-covered, pan-cancer genomic profiling test. The company exited 2023 with $114 million in cash and restricted deposits — management expects cash runway into 2026 based on current operating plans — and closed a $26 million direct equity offering in January 2024. Headcount stood at ~225 at year-end 2023, down from 290 the prior year, after a restructuring that centralized commercial operations in Fremont and trimmed R&D overlap. What structurally separates Personalis from sequencers like Guardant Health or Exact Sciences is the deliberate focus on immunogenomics depth over clinical throughput. The platform returns not a gene list but a systems-level read on neoantigen prediction, HLA typing, and MHC class presentation — data layers that biomarker leads inside pharma use to stratify trial arms and salvage failed drugs. Hall’s predecessor John West presided over a period of $100M-plus annual investment in this infrastructure, and the current management team is monetizing it through enterprise licensing rather than attempting to out-market an existing diagnostic brand. The VA contract and the undisclosed top-5 pharma relationship account for over half of revenue, giving the company concentration risk but also a durable, contracted-through-2028 footprint in largest-scale genomic research.
General information
Firm type
Unclassified
Year founded
2010
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Fremont
Corporate office
Fremont, CA, United States
Principals
Christopher Hall
President and CEO
Sector focus
Frequently asked questions
How does Personalis's technology differ from Guardant Health or Exact Sciences?
Personalis sequences whole-exome and transcriptome DNA plus RNA, capturing not just tumor mutations but the immune microenvironment and neoantigen prediction that panel-based tests from Guardant or Exact miss. This immunogenomics output targets the biomarker-discovery end of biopharma R&D rather than high-volume clinical screening. The result is a richer molecular readout but slower turnaround and higher per-sample cost, which is why the company competes for pharma trial contracts rather than community-oncology market share.
Who runs investment and capital allocation decisions at Personalis?
Personalis is a publicly traded clinical genomics company (Nasdaq: PSNL), so capital-allocation decisions rest with President and CEO Christopher Hall and the board of directors. The board includes representatives from Merck Global Health Innovation Fund and ARK Invest, reflecting the strategic-pharma and smart-beta institutional ownership that shapes financing decisions. Day-to-day R&D investment allocation runs through the executive team in Fremont, California.
What is the VA Million Veteran Program relationship worth to Personalis?
The VA contract is the company's single largest revenue source, representing roughly 40% of 2022 revenue before the program slowed new enrollment in 2023. The contract runs through 2025 with an option to extend, and Personalis has sequenced over 150,000 veterans as of the 2023 annual report. While per-sample revenue from the VA is lower than biopharma contracts, the program provides unmatched genomic-scale data that strengthens the company's NeXT platform algorithms.
Does Personalis generate revenue from Medicare-reimbursed clinical tests?
Yes. The company's NeXT Dx profile, which analyzes 20,000 genes and includes PD-L1, TMB, MSI, and HER2 amplification status, has been Medicare-covered since 2022. Clinical testing is sold through a small internal sales team, not through a large commercial channel partner, so volume remains modest relative to biopharma services revenue. Medicare coverage provides a floor for the clinical business but does not drive the top-line growth story.
How is Personalis funded, and what is its cash position?
As of December 31, 2023, the company held $114 million in cash, cash equivalents, and restricted deposits. In January 2024 it raised an additional $26 million through a direct equity offering to funds managed by ARK Invest and Merck Global Health Innovation Fund. Management guidance indicates cash runway through 2026 based on current operating plans, which prioritize biopharma contract growth over clinical volume expansion.
What investment stages does Personalis typically target?
Personalis is a genomic-sequencing services company, not an investment firm — it does not deploy capital into external portfolios or funds. For allocators, the relevant question is where Personalis fits in a public-equity portfolio: it is a small-cap, pre-profitability clinical genomics company with heavy pharma contract concentration, trading at a fraction of its 2021 peak. The investment thesis centers on whether the NeXT platform becomes the standard for cancer immunotherapy trial stratification before the $114 million cash runway depletes.
Which sectors does Personalis explicitly avoid?
The company does not operate in consumer genomics, ancestry testing, reproductive health, or agricultural biotech — its entire platform is optimized for oncology biomarker discovery and clinical trial support. Early-stage cancer screening (competing with Grail and Exact) remains outside the current commercial focus, though the underlying whole-genome technology could theoretically apply to broader screening should the company pivot.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: